Health Condition 1: null- Hypertension
Conditions
Interventions
Intervention1: Telmisartan and Amlodipine Combination: Telmisartan 40 mg and Amlodipine 5 mg combination, once daily, orally for 8 Weeks. Both are anti-hypertensive drugs marketed in India
Control Int
Sponsors
Self
Eligibility
Inclusion criteria
Inclusion criteria: 1 Hypertensive patients with uncontrolled blood pressure (Systolic BP >= 140 to 179 mmHg and/or Diastolic BP >= 90 to 109 mmHg) on low dose monotherapy with either Amlodipine ( 2 Age 18 to 60 years, either gender. 3 Patients who are willing to participate and sign consent document. 4 Patient willing to comply with the protocol requirements.
Exclusion criteria
Exclusion criteria: 1 Secondary Hypertension. 2 Clinically evident concomitant disorder such as cardiovascular, renal, hepatic, endocrine, neurological, psychiatric or other complicating diseases or severe co-morbidities. 3 Pregnant or lactating women. 4 Female patients of childbearing potential who do not agree to remain abstinent or use medically acceptable methods of contraception during the study period. 5 Patients with known hypersensitivity to any of the test drug. 6 Patients with alcohol or drug dependence. 7 Patients with stage 3 hypertension (Systolic BP >= 180 mmHg and/or Diastolic BP >= 110 mmHg) 8 Patients who had any major surgery within 4 weeks of screening. 9 Any other condition that in the opinion of the Investigator that does not justify the patientâ??s participation in the study.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Improvement in Blood Pressure Control from BaselineTimepoint: 56 Days of Study Duration | — |
Secondary
| Measure | Time frame |
|---|---|
| Improvement in symptoms associated with high blood pressureTimepoint: 56 Days of Study Duration | — |
Countries
India
Contacts
Public ContactJaswant Goyal
Mahatma Gandhi Medical College and Hospital
Outcome results
None listed